flucytosine has been researched along with Adenocarcinoma in 15 studies
Flucytosine: A fluorinated cytosine analog that is used as an antifungal agent.
flucytosine : An organofluorine compound that is cytosine that is substituted at position 5 by a fluorine. A prodrug for the antifungal 5-fluorouracil, it is used for the treatment of systemic fungal infections.
Adenocarcinoma: A malignant epithelial tumor with a glandular organization.
| Excerpt | Relevance | Reference |
|---|---|---|
| "The bleak prognosis associated with pancreatic cancer (PDAC) drives the need for the development of novel treatment methodologies." | 1.42 | Annexin V-Directed Enzyme Prodrug Therapy Plus Docetaxel for the Targeted Treatment of Pancreatic Cancer. ( Guillen, KP; Harrison, RG; Kurkjian, C; Restuccia, A, 2015) |
| "CD-MSC toxicity on murine prostate cancer cells and tumour tropism were verified in vitro and ex-vivo before starting the preclinical studies." | 1.40 | Mesenchymal stem cells expressing therapeutic genes induce autochthonous prostate tumour regression. ( Abrate, A; Altaner, C; Benigni, F; Bettiga, A; Buono, R; Canu, T; Cavarretta, IT; Colciago, G; Del Maschio, A; Esposito, A; Guazzoni, G; Hedlund, P; Lucianò, R; Montorsi, F, 2014) |
| " The dosing schedule required 30 days; neither addition of an enzyme inhibitor that increases the half-life of fluorocytosine nor intralumenal drug delivery is effective in shortening (to 15 days) the protocol." | 1.30 | Toxin gene-mediated growth inhibition of lung adenocarcinoma in an animal model of pleural malignancy. ( Batra, RK; Boucher, RC; Hoganson, DK; Matsui, H, 1998) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 3 (20.00) | 18.2507 |
| 2000's | 8 (53.33) | 29.6817 |
| 2010's | 4 (26.67) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Kazlauskas, A | 1 |
| Darinskas, A | 1 |
| Meškys, R | 1 |
| Tamašauskas, A | 1 |
| Urbonavičius, J | 1 |
| Abrate, A | 1 |
| Buono, R | 1 |
| Canu, T | 1 |
| Esposito, A | 1 |
| Del Maschio, A | 1 |
| Lucianò, R | 1 |
| Bettiga, A | 1 |
| Colciago, G | 1 |
| Guazzoni, G | 1 |
| Benigni, F | 1 |
| Hedlund, P | 1 |
| Altaner, C | 2 |
| Montorsi, F | 1 |
| Cavarretta, IT | 1 |
| Guillen, KP | 1 |
| Restuccia, A | 1 |
| Kurkjian, C | 1 |
| Harrison, RG | 1 |
| Bezborodova, OA | 1 |
| Nemtsova, ER | 1 |
| Gevorkov, AR | 1 |
| Boyko, AV | 1 |
| Venediktova, JB | 1 |
| Alekseenko, IV | 1 |
| Kostina, MB | 1 |
| Monastyrskaya, GS | 1 |
| Sverdlov, ED | 1 |
| Khmelevskiy, EV | 1 |
| Yakubovskaya, RI | 1 |
| Pastorakova, A | 1 |
| Hlubinova, K | 1 |
| Li, Q | 1 |
| Huang, ZH | 1 |
| Yu, JL | 1 |
| Su, GQ | 1 |
| Li, Z | 1 |
| Fogar, P | 1 |
| Navaglia, F | 1 |
| Basso, D | 1 |
| Greco, E | 1 |
| Zambon, CF | 1 |
| Fadi, E | 1 |
| Falda, A | 1 |
| Stranges, A | 1 |
| Vannozzi, F | 1 |
| Danesi, R | 1 |
| Pedrazzoli, S | 1 |
| Plebani, M | 1 |
| Negroni, L | 1 |
| Samson, M | 1 |
| Guigonis, JM | 1 |
| Rossi, B | 1 |
| Pierrefite-Carle, V | 1 |
| Baudoin, C | 1 |
| Consalvo, M | 1 |
| Mullen, CA | 1 |
| Modesti, A | 1 |
| Musiani, P | 1 |
| Allione, A | 1 |
| Cavallo, F | 1 |
| Giovarelli, M | 1 |
| Forni, G | 1 |
| Hoganson, DK | 1 |
| Matsui, H | 1 |
| Batra, RK | 1 |
| Boucher, RC | 1 |
| Gnant, MF | 1 |
| Puhlmann, M | 2 |
| Alexander, HR | 2 |
| Bartlett, DL | 2 |
| McCart, JA | 1 |
| Lee, J | 1 |
| Hu, Y | 1 |
| Libutti, SK | 1 |
| Uchida, A | 1 |
| O'Keefe, DS | 1 |
| Bacich, DJ | 1 |
| Molloy, PL | 1 |
| Heston, WD | 1 |
| Zhang, S | 1 |
| Yuan, S | 1 |
| Lee, YJ | 1 |
| Lee, H | 1 |
| Borrelli, MJ | 1 |
15 other studies available for flucytosine and Adenocarcinoma
| Article | Year |
|---|---|
Isocytosine deaminase Vcz as a novel tool for the prodrug cancer therapy.
Topics: Adenocarcinoma; Animals; Antimetabolites, Antineoplastic; Brain Neoplasms; Caco-2 Cells; Cell Line, | 2019 |
Mesenchymal stem cells expressing therapeutic genes induce autochthonous prostate tumour regression.
Topics: Adenocarcinoma; Animals; Cell Movement; Cytosine Deaminase; Disease Models, Animal; Flucytosine; Gen | 2014 |
Annexin V-Directed Enzyme Prodrug Therapy Plus Docetaxel for the Targeted Treatment of Pancreatic Cancer.
Topics: Adenine; Adenocarcinoma; Annexin A5; Antineoplastic Combined Chemotherapy Protocols; Carbon-Sulfur L | 2015 |
Antitumor efficacy of combined gene and radiotherapy in animals.
Topics: Adenocarcinoma; Animals; Antimetabolites, Antineoplastic; Cell Line, Tumor; Colonic Neoplasms; Combi | 2016 |
Treatment of human tumor cells by combine gene therapy harnessing plasmids expressing human tumor necrosis factor alpha and bacterial cytosine deaminase suicide gene.
Topics: Adenocarcinoma; Antimetabolites; Breast Neoplasms; Cell Line, Tumor; Combined Modality Therapy; Cyto | 2006 |
[Effect of KDR recombinant adenovirus containing double suicide gene on proliferation of human stomach adneocarcinoma SCG7901 cells].
Topics: Adenocarcinoma; Adenoviridae; Cell Line, Tumor; Cell Proliferation; Cell Survival; Dose-Response Rel | 2007 |
Suicide gene therapy with the yeast fusion gene cytosine deaminase/uracil phosphoribosyltransferase is not enough for pancreatic cancer.
Topics: Adenocarcinoma; Antimetabolites, Antineoplastic; Biotransformation; Cell Line, Tumor; Colorectal Neo | 2007 |
Treatment of colon cancer cells using the cytosine deaminase/5-fluorocytosine suicide system induces apoptosis, modulation of the proteome, and Hsp90beta phosphorylation.
Topics: Adenocarcinoma; Amino Acid Sequence; Animals; Annexin A5; Apoptosis; Biomarkers, Tumor; Blotting, We | 2007 |
5-Fluorocytosine-induced eradication of murine adenocarcinomas engineered to express the cytosine deaminase suicide gene requires host immune competence and leaves an efficient memory.
Topics: Adenocarcinoma; Animals; Combined Modality Therapy; Cytosine Deaminase; Female; Flucytosine; Genetic | 1995 |
Toxin gene-mediated growth inhibition of lung adenocarcinoma in an animal model of pleural malignancy.
Topics: Adenocarcinoma; Animals; Cell Division; Cytosine Deaminase; Disease Models, Animal; Escherichia coli | 1998 |
Systemic administration of a recombinant vaccinia virus expressing the cytosine deaminase gene and subsequent treatment with 5-fluorocytosine leads to tumor-specific gene expression and prolongation of survival in mice.
Topics: Adenocarcinoma; Animals; Antimetabolites, Antineoplastic; Colonic Neoplasms; Cytosine Deaminase; Fem | 1999 |
Complex interactions between the replicating oncolytic effect and the enzyme/prodrug effect of vaccinia-mediated tumor regression.
Topics: Adenocarcinoma; Animals; Colonic Neoplasms; Cytosine Deaminase; Dose-Response Relationship, Drug; Dr | 2000 |
In vivo suicide gene therapy model using a newly discovered prostate-specific membrane antigen promoter/enhancer: a potential alternative approach to androgen deprivation therapy.
Topics: Adenocarcinoma; Animals; Cytosine Deaminase; Flucytosine; Gene Expression; Genes, Reporter; Genetic | 2001 |
[Experimental study on human pancreatic carcinoma treated by cytosine deaminase gene therapy].
Topics: Adenocarcinoma; Adenoviruses, Human; Animals; Antimetabolites, Antineoplastic; Carcinoembryonic Anti | 2000 |
Gene transfer into human prostate adenocarcinoma cells with an adenoviral vector: Hyperthermia enhances a double suicide gene expression, cytotoxicity and radiotoxicity.
Topics: Adenocarcinoma; Adenoviridae; Antiviral Agents; Cell Survival; Cytosine Deaminase; Drug Synergism; F | 2002 |